AdvaMed seeks to free user fees from sequester; C.R. Bard closes $262M deal to buy Rochester Medical;

@FierceMedDev: Trending on FierceMedicalDevices: Report: J&J plans layoffs, revamp to jumpstart diabetes arm. Story | Follow @FierceMedDev

@MarkHFierce: NeuroPace won the FDA's blessing for a neurostimulation implant to treat epilepsy. More | Follow @MarkHFierce

@MichaelGFierce: Next-gen sequencing tech from GenapSys nets $37M round. Item | Follow @MichaelGFierce

> AdvaMed renewed a call to Congress to support bipartisan legislation that would exempt all FDA user fees from the sequester, which has pulled $2.9 million in user fees from the FDA's device center so far this year. Item

> C.R. Bard ($BCR) has closed its $262 million acquisition of Rochester Medical. Story

> Retractable Technologies ($RVP), a Texas maker of syringe, blood collection and IV catheter devices, said its operating expenses soared 13.7% during the quarter ending Sept. 30, partly due to the 2.3% medical device tax. Item

> Svelte Medical Systems said it enrolled its final patient in a study comparing its drug-eluting coronary stent integrated delivery system to Medtronic's ($MDT) Resolute Integrity product. Item

> A Malawi partnership that developed a low-cost medical device to ease the breathing of newborn babies won the largest funding from the first GlaxoSmithKline ($GSK)/Save the Children $1 million Healthcare innovation Award. Item

> Corgenix has filed for de novo 510(k) clearance for its hyaluronic acid ELISA test kit, which looks for liver fibrosis in nonalcoholic steatohepatitis patients. Item

Biotech News

@FierceBiotech: Baxter bets $60M on Cell Therapeutics' blood cancer drug. Article | Follow @FierceBiotech

@JohnCFierce: Vanda jumps again as FDA panel smiles on sleep-disorder drug. More | Follow @JohnCFierce

@DamianFierce: ICYMI: Sanofi gets mixed FDA blessing for MS drug Lemtrada. Story | Follow @DamianFierce

@EmilyMFierce: From FierceBiotech Research: Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. Article | Follow @EmilyMFierce

> Catabasis nails $32.4M for triglyceride-busting drug. News

> Zafgen obesity drug scores heavyweight success in PhII trial. More

> Relax, PCSK9ers: FDA won't roadblock blockbusters from Sanofi, Amgen. Story

Pharma News

@FiercePharma: So, if you're not among the 103K people who have already, check it out. Report | Follow @FiercePharma

@EricPFierce: With a market as big as China, you can't let a bribery case scare you away. J&J, Merck to build new plants. More | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from biotech products. More | Follow @CarlyHFierce

> GSK expanding further in India with £85M facility, CEO Witty says. News

> Drugmakers confront new pay-to-delay cases under new rules. Report